Physician profile
Daniel Wu
NPI 1932519790
$1,501.23
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,358 · 2020: $115 · 2021: $28.14.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $345.52 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $230.95 | 2019-2020 | |
| Lilly USA, LLC | $183.76 | 2019 | |
| Alexion Pharmaceuticals, INC. | $127.51 | 2019 | |
| Genentech USA, INC. | $93.74 | 2019 | |
| Incyte Corporation | $74.56 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $64.46 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $52.53 | 2019 | |
| Pfizer INC. | $48.94 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.71 | 2019 | |
| Kite Pharma, INC. | $28.49 | 2020 | |
| Celgene Corporation | $24.98 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $24.67 | 2019 | |
| Amgen INC. | $24.34 | 2019 | |
| Genzyme Corporation | $24.17 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $23.49 | 2019 | |
| Seagen INC. | $22.83 | 2019 | |
| Stemline Therapeutics INC. | $22.60 | 2019 | |
| Gilead Sciences, INC. | $21.22 | 2019 | |
| Exelixis INC. | $20.76 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.